Clinical Trial

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients with CLDN18.2 positivity.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-26
Trial Details
NCT Number NCT07385703
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions Adenocarcinoma
Enrollment 752 participants
Start Date 2026-04-15
Primary Completion 2028-10 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-25